rs142761835
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_002225.5(IVD):c.358G>A(p.Gly120Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000273 in 1,614,074 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 11/19 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_002225.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
IVD | NM_002225.5 | c.358G>A | p.Gly120Arg | missense_variant | 4/12 | ENST00000487418.8 | NP_002216.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
IVD | ENST00000487418.8 | c.358G>A | p.Gly120Arg | missense_variant | 4/12 | 1 | NM_002225.5 | ENSP00000418397.3 |
Frequencies
GnomAD3 genomes AF: 0.000112 AC: 17AN: 152182Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000278 AC: 7AN: 251468Hom.: 0 AF XY: 0.0000294 AC XY: 4AN XY: 135918
GnomAD4 exome AF: 0.0000185 AC: 27AN: 1461892Hom.: 0 Cov.: 32 AF XY: 0.0000261 AC XY: 19AN XY: 727248
GnomAD4 genome AF: 0.000112 AC: 17AN: 152182Hom.: 0 Cov.: 33 AF XY: 0.0000942 AC XY: 7AN XY: 74338
ClinVar
Submissions by phenotype
Isovaleryl-CoA dehydrogenase deficiency Pathogenic:7
Likely pathogenic, criteria provided, single submitter | literature only | Counsyl | Apr 04, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 30, 2023 | Variant summary: IVD c.358G>A (p.Gly120Arg) results in a non-conservative amino acid change in the encoded protein sequence. Four of four in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 251468 control chromosomes (gnomAD). c.358G>A (also known as c.367G>A, p.G123R) has been reported in the literature in multiple homozygous individuals affected with Isovaleryl-CoA Dehydrogenase Deficiency (examples: Carling_2018 and Dercksen_2012). At least one publication reports experimental evidence evaluating an impact on protein function. IVD enzyme activity from 10 homozygous individuals were below the quantification level (LOQ) of the validated assay (Dercksen_2012). These data indicate that the variant is very likely to be associated with disease. Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 18, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Department Of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University | Dec 30, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 13, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 29, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 123 of the IVD protein (p.Gly123Arg). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individuals with isovaleric acidemia (PMID: 22004070, 22350545, 27904153; Invitae). It has also been observed to segregate with disease in related individuals. This variant is also known as c.358G>A (p.Gly91Arg). ClinVar contains an entry for this variant (Variation ID: 167199). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. This variant disrupts the p.Gly123 amino acid residue in IVD. Other variant(s) that disrupt this residue have been observed in individuals with IVD-related conditions (PMID: 15486829), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 18, 2017 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Mar 16, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 09, 2022 | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Also known as p.(G91R) or p.(G120R); This variant is associated with the following publications: (PMID: 25087612, 15486829, 22350545, 32778825, 28535199, 28631226, 27904153, 22004070, 31442447) - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 30, 2024 | The c.367G>A (p.G123R) alteration is located in exon 4 (coding exon 4) of the IVD gene. This alteration results from a G to an A substitution at nucleotide position 367, causing the glycine (G) at amino acid position 123 to be replaced by an arginine (R). Based on data from gnomAD, the A allele has an overall frequency of 0.004% (10/282872) total alleles studied. The highest observed frequency was 0.024% (6/24970) of African alleles. This alteration was detected in the homozygous state in multiple individuals with Isovaleric acidemia (Carling, 2018; Couce, 2017; Dercksen, 2012). This amino acid position is not well conserved in available vertebrate species. This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
IVD-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 05, 2023 | The IVD c.367G>A variant is predicted to result in the amino acid substitution p.Gly123Arg. This variant (also referred to in the literature as c.358G>A or p.Gly91Arg) has been reported with a second IVD variant or in the homozygous state in a number of individuals with isovaleric acidemia (Vatanavicharn et al. 2011. PubMed ID: 22004070; Dercksen et al. 2012. PubMed ID: 22350545; Couce et al. 2017. PubMed ID: 27904153; Carling et al. 2018. PubMed ID: 28631226). In fibroblasts from patients described by Derckesen et al. (2012), isovaleryl-CoA dehydrogenase activity was undetectable and protein levels were markedly reduced. We have also observed this variant internally in a number of presumably affected individuals. Based on these observations, we classify this variant as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at